No Data
Healthcare Venture Investors Ante Up. Public Markets Remain Cool. -- Barrons.com
SPDR S&P Biotech ETF To Go Ex-Dividend On September 23rd, 2024 With 0.01523 USD Dividend Per Share
Halozyme Cut to Neutral at J.P. Morgan on Valuation
These four companies that are about to debut on the US stock market are worth focusing on. They may reverse the downturn in Biotech IPOs.
BioAge and Bicara hope to reverse the recent trend of obstacles in biotech companies' IPO in the US stock market; The binary nature of drug development has kept some investors away from the biotech industry.
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue. -- Barrons.com
Morgan Stanley Stays Bullish on AI, Obesity, and Defense Focused Themes